Argenica Therapeutics 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Liz Dallimore

최고 경영자

AU$424.2k

총 보상

CEO 급여 비율	67.8%
CEO 임기	2.6yrs
CEO 소유권	1.3%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Liz Dallimore 의 보수는 Argenica Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$424k	AU$288k	-AU$5m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$5m
Sep 30 2023	n/a	n/a	-AU$5m
Jun 30 2023	AU$675k	AU$250k	-AU$5m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$4m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	AU$337k	AU$228k	-AU$4m
Mar 31 2022	n/a	n/a	-AU$3m
Dec 31 2021	n/a	n/a	-AU$3m
Sep 30 2021	n/a	n/a	-AU$2m
Jun 30 2021	AU$145k	AU$31k	-AU$1m

보상 대 시장: Liz 의 총 보상 ($USD 278.14K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 299.68K ).

보상과 수익: Liz 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Liz Dallimore

2.6yrs

테뉴어

AU$424,246

보상

Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD, GAICD) serves as Chief Executive Officer of Argenica Therapeutics Limited ands serves as its Managing Director and Director since April 4, 2022. She is a researc...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Liz Dallimore	CEO, MD & Director	2.6yrs	AU$424.25k	1.28% A$ 1.2m
Dianne Angus	Independent Non-Executive Chairman	less than a year	AU$102.58k	데이터 없음
Geoffrey Donnan	Member of Clinical Advisory Committee	no data	데이터 없음	데이터 없음
Terence Budge	Independent Non-Executive Director	3.8yrs	AU$44.40k	0.63% A$ 600.2k
Elizabeth McCall	Independent Non-Executive Director	3.9yrs	AU$44.40k	0.35% A$ 330.2k
Robert Black	Independent Non-Executive Director	less than a year	데이터 없음	0.020% A$ 18.6k
Paul Bailey	Member of Clinical Advisory Committee	no data	데이터 없음	데이터 없음
Tim Phillips	Member of Clinical Advisory Committee	no data	데이터 없음	데이터 없음
David Blacker	Chairman of Clinical Advisory Committee	no data	데이터 없음	데이터 없음
Jeffery Saver	Member of Clinical Advisory Committee	2.3yrs	데이터 없음	데이터 없음
Mark Etherton	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

경험이 풍부한 이사회: AGN 의 이사회는 경험(평균 재직 기간 2.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Argenica Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Ms. Liddy Mccall Intends Not Stand for Re-Election as Non-Executive Director of Argenica Therapeutics Limited

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Less than half of directors are independent

Recent updates

Ms. Liddy Mccall Intends Not Stand for Re-Election as Non-Executive Director of Argenica Therapeutics Limited

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

New minor risk - Share price stability

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

New major risk - Share price stability

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Less than half of directors are independent

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간